

Evgeny Arons

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2774374/publications.pdf>

Version: 2024-02-01

33
papers

940
citations

758635

12
h-index

525886

27
g-index

33
all docs

33
docs citations

33
times ranked

882
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues. <i>Blood Reviews</i> , 2022, 51, 100888.	2.8	4
2	Phase 1 trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox combined with rituximab for relapsed/refractory hairy cell leukemia.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7036-7036.	0.8	0
3	Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant. <i>Blood Advances</i> , 2021, 5, 4807-4816.	2.5	13
4	Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 1527-1538.	0.8	58
5	Expression of the muscle-associated gene MYF6 in hairy cell leukemia. <i>PLoS ONE</i> , 2020, 15, e0227586.	1.1	5
6	In search of genetic factors predisposing to familial hairy cell leukemia (HCL): exome-sequencing of four multiplex HCL pedigrees. <i>Leukemia</i> , 2020, 34, 1934-1938.	3.3	3
7	Generation of antibody-based therapeutics targeting the idiotype of B-cell malignancies. <i>Antibody Therapeutics</i> , 2019, 2, 12-21.	1.2	2
8	Differential Expression of CD43, CD81, and CD200 in Classic Versus Variant Hairy Cell Leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 275-282.	0.7	20
9	Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant. <i>Blood</i> , 2019, 134, 1536-1536.	0.6	1
10	Randomized phase II study of cladribine with simultaneous or delayed rituximab in patients with untreated hairy cell leukemia.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7003-7003.	0.8	5
11	Impact of telomere length on survival in classic and variant hairy cell leukemia. <i>Leukemia Research</i> , 2015, 39, 1360-1366.	0.4	8
12	High Response Rate of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia Includes Eradication of Minimal Residual Disease: Potential Importance for Outcome. <i>Blood</i> , 2015, 126, 4161-4161.	0.6	3
13	Moxetumomab pasudotox and minimal residual disease in hairy cell leukemia.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7079-7079.	0.8	1
14	Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome. <i>British Journal of Haematology</i> , 2014, 166, 729-738.	1.2	13
15	High prevalence of MAP2K1 mutations in variant and IGHV4-34â€‘expressing hairy-cell leukemias. <i>Nature Genetics</i> , 2014, 46, 8-10.	9.4	236
16	Cladribine with Immediate Rituximab for the Treatment of Patients with Variant Hairy Cell Leukemia. <i>Clinical Cancer Research</i> , 2013, 19, 6873-6881.	3.2	62
17	Pharmacokinetic Analysis Of Response In Hairy Cell Leukemia Treated By Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox. <i>Blood</i> , 2013, 122, 2871-2871.	0.6	4
18	Both variant and IGHV4-34â€‘expressing hairy cell leukemia lack the BRAF V600E mutation. <i>Blood</i> , 2012, 119, 3330-3332.	0.6	202

#	ARTICLE	IF	CITATIONS
19	Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Blocks Hairy Cell Leukemia (HCL) Survival, Proliferation, and BCR Signaling: A New Therapeutic Approach for HCL. <i>Blood</i> , 2012, 120, 1802-1802.	0.6	5
20	Resolution of Hairy Cell Leukemia Minimal Residual Disease by Both BRAF and Clone-Specific Real-Time Quantitative PCR (RQ-PCR) After Treatment with Moxetumomab Pasudotox.. <i>Blood</i> , 2012, 120, 2896-2896.	0.6	1
21	Durability of complete remission by moxetumomab pasudotox (HA22 or CAT-8015) assessed by clone-specific real-time quantitative PCR (RQ-PCR).. <i>Journal of Clinical Oncology</i> , 2012, 30, 2503-2503.	0.8	0
22	The HLA-DRB1*11 Antigen Is Preferentially Expressed in Hairy Cell Leukemia, Particularly in Patients Who Had Hemolytic Uremic Syndrome with Recombinant Immunotoxin BL22.. <i>Blood</i> , 2012, 120, 2488-2488.	0.6	0
23	Molecular variant of hairy cell leukemia with poor prognosis. <i>Leukemia and Lymphoma</i> , 2011, 52, 99-102.	0.6	24
24	Evidence of canonical somatic hypermutation in hairy cell leukemia. <i>Blood</i> , 2011, 117, 4844-4851.	0.6	31
25	Interim Results of Secondary Endpoints From a Randomized Trial of Cladribine with Early Vs Delayed Rituximab for Treatment of Early Hairy Cell Leukemia. <i>Blood</i> , 2011, 118, 2856-2856.	0.6	0
26	Bendamustine and Rituximab for the Treatment of Multiply Relapsed Hairy Cell Leukemia,. <i>Blood</i> , 2011, 118, 3909-3909.	0.6	0
27	Presence and Absence of the BRAF V600E Mutation in Hairy Cell Leukemia and Its Variants. <i>Blood</i> , 2011, 118, 931-931.	0.6	0
28	VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. <i>Blood</i> , 2009, 114, 4687-4695.	0.6	143
29	PRAME expression in hairy cell leukemia. <i>Leukemia Research</i> , 2008, 32, 1400-1406.	0.4	5
30	Immunoglobulin light chain repertoire in hairy cell leukemia. <i>Leukemia Research</i> , 2007, 31, 1231-1236.	0.4	7
31	Somatic hypermutation and VH gene usage in hairy cell leukaemia. <i>British Journal of Haematology</i> , 2006, 133, 504-512.	1.2	35
32	Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 1100-1110.	2.0	16
33	Minimal Residual Disease in Hairy Cell Leukemia Patients Assessed by Clone-Specific Polymerase Chain Reaction. <i>Clinical Cancer Research</i> , 2006, 12, 2804-2811.	3.2	33